The DOI matches its Crossref record; 256 of the 256 references it cites were found in a registry or an index.
The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF
Open accessAbstract
Angiogenesis is a double-edged sword; it is a mechanism that defines the boundary between health and disease. In spite of its central role in physiological homeostasis, it provides the oxygen and nutrition needed by tumor cells to proceed from dormancy if pro-angiogenic factors tip the balance in favor of tumor angiogenesis. Among pro-angiogenic factors, vascular endothelial growth factor (VEGF) is a prominent target in therapeutic methods due to its strategic involvement in the formation of anomalous tumor vasculature. In addition, VEGF exhibits immune-regulatory properties which suppress immune cell antitumor activity. VEGF signaling through its receptors is an integral part of tumoral angiogenic approaches. A wide variety of medicines have been designed to target the ligands and receptors of this pro-angiogenic superfamily. Herein, we summarize the direct and indirect molecular mechanisms of VEGF to demonstrate its versatile role in the context of cancer angiogenesis and current transformative VEGF-targeted strategies interfering with tumor growth.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–256 of 256
Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab
Mitsuhashi, A., Goto, H., Saijo, A., Trung, V. T., Aono, Y., Ogino, H., Kuramoto, T., Tabata, S., Uehara, H., Izumi, K., et al. (2015) · Nature Communications · doi:10.1038/ncomms9792 · Cited by 79
Marech, I., Leporini, C., Ammendola, M., Porcelli, M., Gadaleta, C. D., Russo, E., Sarro, G. D., & Ranieri, G. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.028 · Cited by 74
Nath, J., Paul, R., Ghosh, S. K., Paul, J., Singha, B., & Debnath, N. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118189 · Cited by 71
Okikawa, S., Morine, Y., Saito, Y., Yamada, S., Tokuda, K., Teraoku, H., Miyazaki, K., Yamashita, S., Ikemoto, T., Imura, S., et al. (2022) · Oncology Reports · doi:10.3892/or.2022.8282 · Cited by 70
Interplay of vascular endothelial growth factor receptors in organ-specific vessel maintenance
Karaman, S., Paavonsalo, S., Heinolainen, K., Lackman, M. H., Ranta, A., Hemanthakumar, K. A., Kubota, Y., & Alitalo, K. K. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20210565 · Cited by 67
Ichikawa, K., Miyano, S. W., Minoshima, Y., Matsui, J., & Funahashi, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-59853-z · Cited by 65
Shi, Y., Bingle, L., Gong, L. H., Wang, Y., Corke, K. P., & Fang, W. (2007) · Pathology · doi:10.1080/00313020701444549 · Cited by 61
Yeh, C.-C., Hsu, C., Shao, Y., Ho, W.-C., Tsai, M., Feng, W.-C., & Chow, L. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.046417 · Cited by 61
Hutson, T. E., Al-Shukri, S. K., Stus, V. P., Lipatov, O. N., Shparyk, Y. V., Bair, A. H., Rosbrook, B., Andrews, G. I., & Vogelzang, N. J. (2016) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.05.008 · Cited by 61
Intussusceptive angiogenesis as a key therapeutic target for cancer therapy
Sekaran, S., Vimalraj, S., Koka, P., Nikarika, R., & Sumantran, V. N. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117670 · Cited by 61
Tu-gang, C. H. E. N., Zhong, Z., Sun, G.-F., Zhou, Y.-X., & Zhao, Y. (2011) · Cell Proliferation · doi:10.1111/j.1365-2184.2011.00764.x · Cited by 60
Benjamin, R. S., Schöffski, P., Hartmann, J. T., van Oosterom, A., Bui, B., Duyster, J., Schuetze, S. M., Blay, J., Reichardt, P., Rosen, L. S., et al. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1431-9 · Cited by 60
Potent inhibition of tumoral hypoxia-inducible factor 1α by albendazole
Pourgholami, M. H., Cai, Z. Y., Badar, S., Wangoo, K., Poruchynsky, M. S., & Morris, D. L. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-143 · Cited by 59
Self-citationDanilucci, T. M., dos Santos, P. K., Pachane, B. C., Pisani, G. F. D., Lino, R. L. B., Casali, B. C., Altei, W. F., & Selistre-de-Araújo, H. S. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0339-1 · Cited by 58
Targeting neuropilin-1 interactions is a promising anti-tumor strategy
Liu, S.-D., Zhong, L., He, J., & Zhao, Y.-X. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001200 · Cited by 58
Gao, H., Lan, X., Li, S., & Xue, Y. (2017) · Tumor Biology · doi:10.1177/1010428317698368 · Cited by 54
Alternative Vascularization Mechanisms in Tumor Resistance to Therapy
Belotti, D., Pinessi, D., & Taraboletti, G. (2021) · Cancers · doi:10.3390/cancers13081912 · Cited by 54
Zarychta, E., & Ruszkowska-Ciastek, B. (2022) · Biomedicines · doi:10.3390/biomedicines10020300 · Cited by 53
Vascular endothelial growth factor and bevacitumab in breast cancer
Bando, H. (2007) · Breast Cancer · doi:10.2325/jbcs.968 · Cited by 52
Vinik, A. I., Bottomley, A., Korytowsky, B., et al. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0462-5 · Cited by 52
Taş, F., Duranyıldız, D., Oğuz, H., Çamlıca, H., Yasasever, V., & Topuz, E. (2008) · Medical Oncology · doi:10.1007/s12032-008-9058-y · Cited by 50
German, A. E., Mammoto, T., Jiang, E., Ingber, D. E., & Mammoto, A. (2014) · Journal of Cell Science · doi:10.1242/jcs.132316 · Cited by 49
Florio, R., Carradori, S., Veschi, S., Brocco, D., Genni, T. D., Cirilli, R., Casulli, A., Cama, A., & Lellis, L. D. (2021) · Pharmaceuticals · doi:10.3390/ph14040372 · Cited by 43
Kubota, K., Yoshioka, H., Oshita, F., Hida, T., Yoh, K., Hayashi, H., Kato, T., Kaneda, H., Yamada, K., Tanaka, H., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.7297 · Cited by 42
Garon, E. B., Cao, D., Alexandris, E., John, W. J., Yurasov, S., & Pérol, M. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.06.007 · Cited by 40
Zhao, L., Chen, H., Lu, L., Wang, L., Zhang, X., & Guo, X. (2020) · Journal of drug targeting · doi:10.1080/1061186x.2020.1815210 · Cited by 38
Liu, K., Sun, B., Zhao, X., Wang, X., Li, Y., Qiu, Z., Gu, Q., Dong, X., Zhang, Y., Wang, Y., et al. (2015) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2015.08.009 · Cited by 37
Targeting prion-like protein doppel selectively suppresses tumor angiogenesis
Al-Hilal, T. A., Chung, S. W., Choi, J. U., Alam, F., Park, J., Kim, S. W., Kim, S. Y., Ahsan, F., Kim, I.-S., & Byun, Y. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83427 · Cited by 35
Lo, H., Shieh, J., Chen, C.-L., Tsou, C.-J., & Wu, W. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140510090 · Cited by 34
Immune cells regulate VEGF signalling via release of VEGF and antagonistic soluble VEGF receptor-1
Hoeres, T., Wilhelm, M., Smetak, M., Holzmann, E., Schulze-Tanzil, G. G., & Birkmann, J. (2017) · Clinical & Experimental Immunology · doi:10.1111/cei.13090 · Cited by 31
The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis
Noh, K., Bach, D., Choi, H. J., Kim, M. S., Wu, S. Y., Pradeep, S., Ivan, C., Cho, M.-S., Bayraktar, E., Rodriguez‐Aguayo, C., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01517-3 · Cited by 30
Ledermann, J. A., Embleton-Thirsk, A., Perren, T. J., Jayson, G. C., Rustin, G. J. S., Kaye, S. B., Hirte, H. W., Oza, A. M., Vaughan, M. M., Friedlander, M. L., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100043 · Cited by 30
Zhu, J.-Y., Zhang, X., Ai, L., Yuan, R.-D., & Ye, J. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1975-3 · Cited by 29
Intussusceptive Angiogenesis in Human Metastatic Malignant Melanoma
Pandita, A., Ekstrand, M., Bjursten, S., Zhao, Z., Fogelstrand, P., Gal, K. L., Ny, L., Bergö, M. O., Karlsson, J. W., Nilsson, J. A., et al. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.07.009 · Cited by 28
Vascular endothelial growth factor suppresses dendritic cells function of human prostate cancer
Bai, W., Zhang, W., & Hu, B. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s161302 · Cited by 26
The Roles of Tumor Endothelial Cells in Cancer Metastasis
Hida, K., Maishi, N., Takeda, R., & Hida, Y. (2022) · Exon Publications eBooks · doi:10.36255/exon-publications.metastasis.endothelial-cells · Cited by 24
Won, E. S., Basunia, A., Chatila, W. K., Hechtman, J. F., Chou, J. F., Ku, G. Y., Chalasani, S. B., Boyar, M. S., Goldberg, Z., Desai, A. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3789 · Cited by 22
The role of pro- and antiangiogenic factors in angiogenesis process by Raman spectroscopy
Kopec, M., & Abramczyk, H. (2021) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2021.120667 · Cited by 22
VEGF-Mediated Signal Transduction in Tumor Angiogenesis
Napione, L., Alvaro, M., & Bussolino, F. (2017) · InTech eBooks · doi:10.5772/66764 · Cited by 20
Are rapidly growing cancers more lethal?
Adami, H., Csermely, P., Veres, D. V., Emilsson, L., Løberg, M., Bretthauer, M., & Kalager, M. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.11.011 · Cited by 19
Swartz, J. E., Wegner, I., Noorlag, R., van Kempen, P. M. W., van Es, R. J. J., de Bree, R., & Willems, S. M. (2020) · Head & Neck · doi:10.1002/hed.26530 · Cited by 19
Ikaros Proteins in Tumor: Current Perspectives and New Developments
Xia, R., Cheng, Y., Han, X., Wei, Y., & Wei, X. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.788440 · Cited by 19
The Impact of Ramucirumab Treatment on Survival and Quality of Life in Patients with Gastric Cancer
Mehta, R. J., Kommalapati, A., & Kim, R. D. (2020) · Cancer Management and Research · doi:10.2147/cmar.s199827 · Cited by 18
Ramucirumab (Cyramza): A Breakthrough Treatment for Gastric Cancer.
Singh, A. D., & Parmar, S. (2015) · PubMed Central · Cited by 17
Effing, S. M. A., & Gyawali, B. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100458 · Cited by 16
Vascular heterogeneity: VEGF receptors make blood vessels special
Li, P., & Ferrara, N. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20212539 · Cited by 16
Survivin is critically involved in VEGFR2 signaling-mediated esophageal cancer cell survival
Meng, L., Fu-hao, Z., Xiaoming, Z., Yuxiu, Z., Zhaojun, D., Bingcheng, L., Meiling, X., & Shuyan, S. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.05.134 · Cited by 15
Park, M., Kim, J. Y., Kim, J., Lee, J., Kwon, Y., & Kim, Y. (2021) · BMB Reports · doi:10.5483/bmbrep.2021.54.9.096 · Cited by 15
Ileiwat, Z. E., Tabish, T. A., Zinovkin, D. A., Yüzügülen, J., Arghiani, N., & Pranjol, M. Z. I. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.976677 · Cited by 15
Self-citationLee, S.-Y., Lee, A., Lim, J., & Lim, J. (2022) · BMB Reports · doi:10.5483/bmbrep.2022.55.2.114 · Cited by 10
Bulska, W., Czajka‐Francuz, P., Cisoń-Jurek, S., Owczarek, A. J., Francuz, T., & Chudek, J. T. (2022) · Medicina · doi:10.3390/medicina58020153 · Cited by 10
Tisotumab Vedotin: The First FDA-Approved Antibody-Drug Conjugate for Cervical Cancer
De, S. K. (2022) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520622666220421095240 · Cited by 8
Choi, J. U., Zhang, X., Hasan, M. M., Karim, M., Chung, S. W., Alam, F., Alqahtani, F., Reddy, S., Kim, I., Al-Hilal, T. A., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121423 · Cited by 6
Treps, L., Ager, A., & Hida, K. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.885670 · Cited by 6
Ip, E. H., Saldana, S. J., Miller, K. D., Carlos, R. C., Gareen, I. F., Sparano, J. A., Graham, N., Zhao, F., Lee, J., O'Connell, N. S., et al. (2021) · Cancer · doi:10.1002/cncr.33992 · Cited by 4
Boisteau, É., François, É., Aparicio, T., Malicot, K. L., Boulahssass, R., Lecomte, T., Laurent‐Puig, P., Guiu, B., Paillaud, É., Galais, M., et al. (2022) · Digestive and Liver Disease · doi:10.1016/j.dld.2022.03.001 · Cited by 2
Cited by
Research progress on interferon and cellular senescence
Wang, D., Chen, K., Wang, Z., Wu, H., & Li, Y. (2024) · The FASEB Journal · doi:10.1096/fj.202400808rr · Cited by 23
Hypoxic microenvironment in cancer: role in metabolic reprogramming
Sureka, N., Maheshwari, R., Agravat, A., Singhal, S., Zaman, S., Rishi, B., Siraj, F., Zaheer, S., & Misra, A. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1771365 · Cited by 11
Tracing unknown tumor origins with a biological-pathway-based transformer model
Xie, J., Chen, Y., Luo, S., Yang, W., Lin, Y., Wang, L., Ding, X., Tong, M., & Yu, R. (2024) · Cell Reports Methods · doi:10.1016/j.crmeth.2024.100797 · Cited by 9
Metadata
- Authors
- Ghalehbandi, S., Yuzugulen, J., Pranjol, M. Z. I., & Pourgholami, M. H.
- Venue
- European Journal of Pharmacology
- Publisher
- Elsevier BV
- Published
- 2023-06
- Volume
- 949
- Pages
- 175586
- ISSN
- 0014-2999 (ISSN-L)
- OpenAlex
- W4323660090
- Cited by
- 362
- References
- 256
- FWCI
- 26.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.